EA201790688A1 - Новые соединения в качестве ингибиторов nik - Google Patents

Новые соединения в качестве ингибиторов nik

Info

Publication number
EA201790688A1
EA201790688A1 EA201790688A EA201790688A EA201790688A1 EA 201790688 A1 EA201790688 A1 EA 201790688A1 EA 201790688 A EA201790688 A EA 201790688A EA 201790688 A EA201790688 A EA 201790688A EA 201790688 A1 EA201790688 A1 EA 201790688A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
compounds
new connections
cancer
diseases
Prior art date
Application number
EA201790688A
Other languages
English (en)
Other versions
EA030908B1 (ru
Inventor
Джордж Хинд
Патриция Тисселли
Януш Йозеф Кулаговский
Калум Маклеод
Самьюэль Эдвард Манн
Стефен Колин Прайс
Джон Гари Монтана
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201790688A1 publication Critical patent/EA201790688A1/ru
Publication of EA030908B1 publication Critical patent/EA030908B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим средствам, применимым для терапии и/или профилактики у млекопитающего, и в частности к ингибиторам NF-κB-индуцирующей киназы (NIK, также известной как MAP3K14), применимым для лечения заболеваний, таких как рак, воспалительные нарушения, нарушения метаболизма и аутоиммунные нарушения. Настоящее изобретение направлено также на фармацевтические композиции, содержащие такие соединения, на способы получения таких соединений и композиций, а также на применение таких соединений или фармацевтических композиций для предупреждения или лечения заболеваний, таких как рак, воспалительные нарушения, нарушения метаболизма, в том числе ожирение и диабет, а также аутоиммунные нарушения.
EA201790688A 2014-10-23 2015-10-22 Соединения в качестве ингибиторов nik EA030908B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190068 2014-10-23
PCT/EP2015/074437 WO2016062792A1 (en) 2014-10-23 2015-10-22 New compounds as nik inhibitors

Publications (2)

Publication Number Publication Date
EA201790688A1 true EA201790688A1 (ru) 2017-08-31
EA030908B1 EA030908B1 (ru) 2018-10-31

Family

ID=51868764

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790688A EA030908B1 (ru) 2014-10-23 2015-10-22 Соединения в качестве ингибиторов nik

Country Status (13)

Country Link
US (1) US10005776B2 (ru)
EP (1) EP3209662B1 (ru)
JP (1) JP6676048B2 (ru)
KR (1) KR102500071B1 (ru)
CN (1) CN107074855B (ru)
AU (1) AU2015334917B2 (ru)
BR (1) BR112017008045A2 (ru)
CA (1) CA2960336C (ru)
EA (1) EA030908B1 (ru)
ES (1) ES2718557T3 (ru)
IL (1) IL251780B (ru)
MX (1) MX371153B (ru)
WO (1) WO2016062792A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
BR112017025995A2 (pt) 2015-06-04 2018-08-14 Ospedale San Raffaele S.R.L. inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
CA2988011C (en) 2015-06-04 2021-03-23 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
EP3656762A1 (en) 2018-11-26 2020-05-27 Instituto Biomar S.A. Compounds for the treatment of nf-kb-related diseases or disorders
BR112021023796A2 (pt) 2019-05-31 2022-02-08 Janssen Pharmaceutica Nv Inibidores de moléculas pequenas de quinase indutora de nf-capab

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756103A2 (en) * 2004-04-26 2007-02-28 Pfizer, Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) * 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
CA2728767A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CA2827161A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
CN103608014A (zh) * 2011-03-24 2014-02-26 罗楹 激酶抑制剂在治疗和预防炎症疾病中的用途
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors

Also Published As

Publication number Publication date
MX2017005282A (es) 2017-08-15
KR20170066473A (ko) 2017-06-14
CN107074855A (zh) 2017-08-18
EP3209662A1 (en) 2017-08-30
ES2718557T3 (es) 2019-07-02
JP6676048B2 (ja) 2020-04-08
AU2015334917A1 (en) 2017-03-23
WO2016062792A1 (en) 2016-04-28
KR102500071B1 (ko) 2023-02-14
EA030908B1 (ru) 2018-10-31
MX371153B (es) 2020-01-20
AU2015334917B2 (en) 2019-08-29
US10005776B2 (en) 2018-06-26
EP3209662B1 (en) 2019-01-09
IL251780A0 (en) 2017-06-29
CA2960336A1 (en) 2016-04-28
US20170334906A1 (en) 2017-11-23
CA2960336C (en) 2023-03-07
JP2017531681A (ja) 2017-10-26
BR112017008045A2 (pt) 2017-12-19
CN107074855B (zh) 2019-11-05
IL251780B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EA201790688A1 (ru) Новые соединения в качестве ингибиторов nik
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
EA201790908A1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
EA201690657A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
EA201690645A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
SA518391624B1 (ar) Ror- منظمات جاما
EA201692176A1 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM